Angiosarcoma Treatment Market Size & Share, by Treatment (Surgery, Radiotherapy, Chemotherapy, Targeted Therapy, Immunotherapy), Location of Instigation (Hemangiosarcoma, Lymphangiosarcoma), End-Users (Hospitals, Homecare, Ambulatory Care Centre), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5327
  • Published Date: Oct 18, 2023
  • Report Format: PDF, PPT

Companies Dominating the Androgen Treatment Landscape

top-features-companies
    • F. Hoffmann La Roche Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • Bayer AG
    • GlaxoSmithKline plc.
    • Sanofi S.A.
    • Amgen Inc.
    • Merck & Co. Inc.
    • AbbiVie Inc.
    • Eli Lilly and Company
    • Bausch Health

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Novartis announced that the U.S. Food and Drug Administration (FDA) had granted commercial authorization for a multi-product gene therapy manufacturing facility in Durham, North Carolina. This approval allows the 170,000 square foot state-of-the-art facility to manufacture, test and commercialize Zolgensma, as well as produce gene therapy products for current and future clinical trials.
  • Amgen announced the completion of its acquisition of Teneobio, Inc. was previously announced with a cash payment of $900 million. The acquisition includes Teneobio's proprietary specific and multispecific antibody technologies, which complement Amgen's existing antibody capabilities and the BiTE platform, and will enable significant acceleration and efficiency in the discovery and development of new molecules.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5327
  • Published Date: Oct 18, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of cancer and growing technological advancement are some of the major factors anticipated to drive the growth of the angiosarcoma treatment market.

The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2024-2036.

The major players in the market are of Bayer AG, GlaxoSmithKline plc., Sanofi S.A., Amgen Inc., Merck & Co. Inc., AbbiVie Inc., Eli Lilly and Company, Bausch Health, and others.

The surgery segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying